Verdict: PASS. False-positive from the watchlist screen. Real thesis is purely binary on pemvidutide Phase 3 readouts; leading-indicator screens can't see drug-trial outcomes.

What ALT actually is

Late clinical-stage biopharma developing pemvidutide — a dual GLP-1/glucagon receptor agonist (1:1 ratio) for MASH (metabolic dysfunction-associated steatohepatitis) and obesity. No commercial product. No meaningful product revenue. Funded by serial equity offerings.

Why the watchlist signal misfired

The peptide-economy first-run summary flagged ALT as the only ticker green on BOTH revenue acceleration (+420%) AND insider buying (+$273K). Both signals are mathematically true and both are noise:

What the financials actually say

• Quarterly revenue: $5K-$37K range over 8 quarters. Most recent: $26K.
• Quarterly net loss: ~$20-30M, consistent.
• Capex: -$79M (TTM) Investing cash flow: −$79.2M (Q4 2025 alone) — correction 2026-08-03: this was the single latest quarter's total investing line (mostly securities-portfolio moves), not TTM and not capex; Altimmune discloses no capex line in the cached filings
• FCF: -$98.6M (TTM) Operating cash flow: −$67.5M TTM (−$19.4M in Q4 2025) — correction 2026-08-03: the −$98.6M was Q4's OCF + total investing cash flow (the pre-July resolver formula), a single quarter mislabeled TTM; with capex undisclosed, true FCF is unknowable from the cache — OCF is the honest burn line
• Recent dilutions (per Massive news):
  • $225M oversubscribed public offering — closed
  • $75M registered direct offering — closed
  • These are last-12-months events; ALT has been issuing equity heavily to fund Phase 3.
• Days-to-cover: 13.71 (significant short overhang — shorts know what the financials say)
• Market cap: $0.6B
• Price: $3.04 (-8.98% 30D)

The real thesis (which we did NOT validate)

If anyone wants to position ALT, the work that matters is:

1. Pemvidutide Phase 3 readout timeline for MASH and obesity (separate trials).
2. Differentiation vs. resmetirom (MDGL — already approved for MASH) and vs. survodutide (NVO/Boehringer dual GLP-1/glucagon, more advanced).
3. Cash runway given the most recent $225M raise vs. trial completion timeline. Probably 2027 readout window — verify.
4. Probability-weighted NPV of Phase 3 success × peak sales × launch curve. Standard biotech option-pricing math.

None of that is in the watchlist signal. The watchlist signal is the noise floor on a binary biotech.

Methodology lesson (keep this)

Leading-indicator composites don't apply to clinical-stage biotechs. The screen was designed for revenue companies. When you point it at a $26K-revenue clinical-stage company, you get green flags from division-by-near-zero. Going forward:

• When a clinical-stage biotech (pre-product, < $50M annualized revenue) flags green on a peptide / biotech / healthcare watchlist screen, default skip the watchlist signal and route to drug-pipeline analysis instead.
• Consider adding a "is this clinical-stage?" tag to the screening output that suppresses the leading-indicator scores below a revenue floor.
• Or: split biotechs into separate "revenue-stage biotech" vs "clinical-stage biotech" watchlists with different signals.

This is the second instance of a screen-level false positive caught by deep-dive validation (first was FTAI Aviation / SOLS being momentum without supply-chain link, captured in a May 4 coverage-validation note). The pattern is now clear enough to record formally.

Sources

• Cash-flow figures in the 2026-08-03 correction re-derived from cash-flow-statements.
• 2026-05-06 (Massive financials + news + 10-K + short-interest)
• peptide-economy (first-pass screen output — the trigger)
• The May 4 FTAI/SOLS coverage validation (a prior false-positive case)

Verdict

PASS as a position. Watchlist keeps ALT for cohort tracking — when LLY/NVO/AMGN move on peptide news, ALT moves with them as cohort beta — but no thesis-driven position. Re-evaluate only on pemvidutide Phase 3 interim/topline.

The methodology observation is filed separately as a research-methodology note.